Brazil's Cristalia gets OK to manufacture biosimilars; Merck KGaA to market anti-aging API

> Brazil's Cristalia has received approval from regulator ANVISA for its facility in São Paulo to manufacture active pharmaceutical ingredients for biologics that it will use to make biosimilars of Roche's ($RHHBY) Herceptin and other drugs. Report (sub. req.)

> Another Indian drugmaker has received a warning letter from the FDA. Letter 

> Jiangsu Nhwa Pharmaceutical says it will invest ¥400 million ($64.63 million) to build an ingredient plant in Xuzhou City. Report

> Indian drugmaker GVK Biosciences says it intends to invest about 100 crore ($16.6 million) to build an active pharmaceutical ingredient plant. Report

> Catalent says it has increased its investment in Redwood Bioscience, which has a platform for making homogeneous antibody-drug conjugates. Report

And Finally... Germany's Merck KGaA has struck an agreement to market an antiaging active pharmaceutical ingredient from California-based Laboratory Skin Care. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.